Interferons in the treatment of human cancer.
The DOI matches its Crossref record.
Abstract
The interferons are the best known of biologic antineoplastic agents. Progress with the clinical application of interferons to cancer has been slow and complicated by the need for attention to a new spectrum of therapeutic and toxic effects manifest by the interferons. This summary of current phase I and II trial results with the interferons establishes their clinical potential. The maximally tolerated dosages of the most common species of interferon alpha produced in eukaryotic cells as well as by recombinant DNA technology in bacteria are now described in a variety of different disease states. "Naturally" produced eukaryotic as well as bacterially synthesized interferons have a similar, wide range of biologic effects in vitro and in vivo. Antiviral, antiproliferative, immunologic, and enzymologic functions of the interferons relevant to antineoplastic functions are under study. Knowledge of these mechanisms should improve the clinical results obtained in human cancer. Species and subspecies differences in the activity of interferons may lead to selective use of the pure interferon subspecies, alone or in combination. The use of the interferons and other antineoplastic biologics, such as antibody or chemotherapy, are subsequent goals that are now on the horizon.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Kirkwood, J. M., Strawderman, M. H., Ernstoff, M. S., Smith, T. J., Borden, E. C., & Blum, R. H. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.1.7 · Cited by 2,094
Self-citationCytokines in the Treatment of Cancer
Conlon, K. C., Miljkovic, M. D., & Waldmann, T. A. (2019) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2018.0019 · Cited by 518
Cytokines in Cancer Immunotherapy
Waldmann, T. A. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028472 · Cited by 507
Hepatotoxicity of Chemotherapy
King, P. D., & Perry, M. C. (2001) · The Oncologist · doi:10.1634/theoncologist.6-2-162 · Cited by 454
The immunology of renal cell carcinoma
Díaz-Montero, C. M., Rini, B. I., & Finke, J. H. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-020-0316-3 · Cited by 442
Immunotherapy of cancer in 2012
Kirkwood, J. M., Butterfield, L. H., Tarhini, A. A., Zarour, H., Kalinski, P., & Ferrone, S. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20132 · Cited by 436
Self-citationClinical investigation of human alpha interferon in chronic myelogenous leukemia
Talpaz, M., Kantarjian, H., McCredie, K., Keating, M., Trujillo, J., & Gutterman, J. (1987) · Blood · doi:10.1182/blood.v69.5.1280.1280 · Cited by 328
Hepatotoxicity of Chemotherapy
Floyd, J., Mirza, I., Sachs, B., & Perry, M. C. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2005.11.002 · Cited by 279
Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma
Llovet, J. M., Sala, M., Castells, L., Suarez, Y., Vilana, R., Bianchi, L., Ayuso, C., Vargas, V., Rodés, J., & Bruix, J. (2000) · Hepatology · doi:10.1002/hep.510310111 · Cited by 271
KIRKWOOD, J. M., ERNSTOFF, M. S., DAVIS, C. A., REISS, M., FERRARESI, R., & RUDNICK, S. A. (1985) · Annals of Internal Medicine · doi:10.7326/0003-4819-103-1-32 · Cited by 173
Self-citationKatlinskaya, Y. V., Katlinski, K. V., Yu, Q., Ortiz, A., Beiting, D. P., Brice, A., Davar, D., Sanders, C., Kirkwood, J. M., Rui, H., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.03.006 · Cited by 108
“…long reported suppressive effects of IFN on growth and survival of established melanoma cells in vitro have been used to provide a foundation for recombinant IFN therapies (Bonnem and Spiegel, 1984; Fisher and Grant, 1985; Kirkwood and Ernstoff, 1985; Kirkwood and Ernstoff, 1984; Sikora, 1980).”
BackgroundSelf-citation
Metadata
- Authors
- Kirkwood, J. M., & Ernstoff, M. S.
- Venue
- Journal of Clinical Oncology
- Published
- 1984-04
- Volume
- 2
- Issue
- 4
- Pages
- 336-352
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1929485758
- Cited by
- 332
- References
- 0
- FWCI
- 13.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.